Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Francesca Romana Ponziani, Silvia Pecere, Loris Lopetuso, Franco Scaldaferri, Giovanni Cammarota & Antonio Gasbarrini. (2016) Rifaximin for the treatment of irritable bowel syndrome – a drug safety evaluation. Expert Opinion on Drug Safety 15:7, pages 983-991.
Read now
Read now
Lucrezia Laterza, Gianluca Ianiro, Iolanda Scoleri, Rosario Landi, Giovanni Bruno, Franco Scaldaferri, Eleonora Gaetani, Mariachiara Campanale & Antonio Gasbarrini. (2015) Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome. Expert Opinion on Pharmacotherapy 16:4, pages 607-615.
Read now
Read now
Brooks D. Cash. (2014) Emerging role of probiotics and antimicrobials in the management of irritable bowel syndrome. Current Medical Research and Opinion 30:7, pages 1405-1415.
Read now
Read now
Articles from other publishers (16)
Cristina Tocia, Irina Magdalena Dumitru, Luana Alexandrescu, Lucian Cristian Petcu & Eugen Dumitru. (2021) Does rifaximin offer any promise in Crohn's disease in remission and concurrent irritable bowel syndrome-like symptoms?. Medicine 100:1, pages e24059.
Crossref
Crossref
Cassandra Kimber, Shiqin Zhang, Cassandra Johnson, Raymond E. West, Alexander J. Prokopienko, Jonathan D. Mahnken, Alan S. Yu, Andrew N. Hoofnagle, Diana Ir, Charles E. Robertson, Makoto Miyazaki, Michel Chonchol, Anna Jovanovich, Bryan Kestenbaum, Daniel N. Frank, Thomas D. Nolin & Jason R. Stubbs. (2020) Randomized, Placebo-Controlled Trial of Rifaximin Therapy for Lowering Gut-Derived Cardiovascular Toxins and Inflammation in CKD. Kidney360 1:11, pages 1206-1216.
Crossref
Crossref
Kichul YoonNayoung Kim, Ju Yup LeeDong Hyun OhA Young SeoChang Yong YunHyuk YoonCheol Min ShinYoung Soo ParkDong Ho Lee. (2018) Clinical Response of Rifaximin Treatment in Patients with Abdominal Bloating. The Korean Journal of Gastroenterology 72:3, pages 121.
Crossref
Crossref
Hyun Jik LeeKyung Sik Park. (2017) Bloating. The Korean Journal of Gastroenterology 70:6, pages 288.
Crossref
Crossref
B. Greenwood-Van Meerveld, R. D. Moloney, A. C. Johnson & M. Vicario. (2016) Mechanisms of Stress-Induced Visceral Pain: Implications in Irritable Bowel Syndrome. Journal of Neuroendocrinology 28:8.
Crossref
Crossref
LIHUA DENG, YANG LIU, DONGSHENG ZHANG, YUAN LI & LIN XU. (2016) Prevalence and treatment of small intestinal bacterial overgrowth in postoperative patients with colorectal cancer. Molecular and Clinical Oncology 4:5, pages 883-887.
Crossref
Crossref
Rachel D. Moloney, Anthony C. Johnson, Siobhain M. O'Mahony, Timothy G. Dinan, Beverley Greenwood-Van Meerveld & John F. Cryan. (2016) Stress and the Microbiota-Gut-Brain Axis in Visceral Pain: Relevance to Irritable Bowel Syndrome. CNS Neuroscience & Therapeutics 22:2, pages 102-117.
Crossref
Crossref
Herbert L. DuPont. (2015) Therapeutic Effects and Mechanisms of Action of Rifaximin in Gastrointestinal Diseases. Mayo Clinic Proceedings 90:8, pages 1116-1124.
Crossref
Crossref
Rachel D. Moloney, Siobhain M. O’Mahony, Timothy G. Dinan & John F. Cryan. (2015) Stress-Induced Visceral Pain: Toward Animal Models of Irritable-Bowel Syndrome and Associated Comorbidities. Frontiers in Psychiatry 6.
Crossref
Crossref
Doron Boltin, Tsachi Tsadok Perets, Einav Shporn, Shoshana Aizic, Sigal Levy, Yaron Niv & Ram Dickman. (2014) Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome. Annals of Clinical Microbiology and Antimicrobials 13:1.
Crossref
Crossref
Antonio Tursi. (2013) Preventing recurrent acute diverticulitis with pharmacological therapies. Therapeutic Advances in Chronic Disease 4:6, pages 277-286.
Crossref
Crossref
A Young Seo, Nayoung Kim & Dong Hyun Oh. (2013) Abdominal Bloating: Pathophysiology and Treatment. Journal of Neurogastroenterology and Motility 19:4, pages 433-453.
Crossref
Crossref
Caroline Schrodt, Erin E. McHugh, Mary Ann Gawinowicz, Herbert L. DuPont & Eric L. Brown. (2013) Rifaximin-Mediated Changes to the Epithelial Cell Proteome: 2-D Gel Analysis. PLoS ONE 8:7, pages e68550.
Crossref
Crossref
Mohammed Saadi & Richard W. McCallum. (2013) Rifaximin in irritable bowel syndrome: rationale, evidence and clinical use. Therapeutic Advances in Chronic Disease 4:2, pages 71-75.
Crossref
Crossref
Franco Scaldaferri, Marco Pizzoferrato, Silvia Pecere, Fabrizio Forte & Antonio Gasbarrini. (2012) Bacterial Flora as a Cause or Treatment of Chronic Diarrhea. Gastroenterology Clinics of North America 41:3, pages 581-602.
Crossref
Crossref
Hoonmo L. KooSaman SabounchiDavid B. HuangHerbert L. Dupont. (2012) Rifaximin Therapy of Irritable Bowel Syndrome. Clinical Medicine Insights: Gastroenterology 5, pages CGast.S7382.
Crossref
Crossref